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MicroRNAs (miRNAs) are ∼22 nucleotide ribonucleic acids (RNA) involved in the post-transcriptional regulation 
of messenger RNAs (mRNA). mRNA regulation is a highly dynamic process, and miRNAs are profound effectors 
in this regulatory pathway. Cancers and other human diseases have elevated and decreased levels of specific 
miRNAs in circulation. The measurement of these miRNAs as biomarkers is a highly competitive area, given 
that early detection is critical for the overall survival of patients. To date, we still do not have any FDA approved 
miRNA assay. There is a wealth of data concerning miRNA expression in blood and tissue in a multitude of 
cancers and non-cancer diseases. Despite this, very few studies overlap in their identification of similar miRNA 
species, and we need to understand this lack of inconsistency. 
There are numerous issues and major hurdles for the application of blood-based miRNAs, and we begin by 
suggesting a framework for standardizing miRNA testing in a clinical setting. A framework is necessary for 
eliminating errors between laboratories or testing sites. Moving forward, we then discuss the role of new 
technologies. We also evaluate the contribution of data analytics, and whether this approach will drive the next 
evolution of miRNA clinical research. 
Standardization and automation
Standardization and automation are the cornerstones of pathology testing, permitting the robust detection 
of human diseases. Standardization coupled with automation eliminates variation between laboratories and 
errors associated with manual handling of specimens. Researchers in the field of miRNA biomarkers must 
adopt standardized guidelines for specimen collection, blood processing, and isolation techniques. Open source 
sharing of data without intellectual property constraints will also accelerate progress in finding consistency 
between studies. These challenges are not insurmountable, as pathology services and collection centers are 
already established in most countries. All that is required is an impetus for instilling our miRNA biomarker 
studies into this framework. 
There is also an urgent necessity to formulate standard operating procedures for miRNA extraction from blood. 
All extraction protocols must be applied on a global scale, reducing the variation associated with different 
extraction methods. There are various approaches to isolating miRNAs, ranging from liquid-based guanidine 
isothiocyanate to silica columns. All have merits, but a consensus must be reached for ensuring consistency 
between different cohort studies. 
Operating procedures must also extend to the detection of these miRNAs. Quantitative PCR (qPCR) data and 
next generation sequencing are the chief detection tools. Consolidating a universal miRNA extraction and 
detection pipeline will directly impact our ability to translate these miRNAs into the clinic. When these issues 
in collection, processing, and detection are resolved, there will be an enormous potential to use blood-based 
miRNAs as a screening program. Early screening and detection is one of the major factors in improving overall 
survival. 
Research consortiums to accelerate clinical interest in miRNAs
In recent years, there has been a push for establishing large consortiums for miRNA research resulting in the 
generation of global surveys for miRNA expression patterns. These include programs such as the Circulating 
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Cell-Free Genome Atlas (CCGA), The Cancer Genome Atlas (TCGA), STRIVE Study, and FANTOM5. Several 
teams have curated the vast information and have developed websites for mining this data1,2. 
View the data: FANTOM5 miRNA data
View the data: A comprehensive, cell specific microRNA catalogue of human peripheral blood
Consortium-based research is also essential for aligning technical standardization across many different studies. 
Consortiums will also have funding support to run unbiased high-throughput screens in the discovery cohort, the 
most important stage. This improves the power and replicability of a study by detecting and quantifying large 
numbers of miRNAs in circulation. Multinational consortiums would agree on specific methodologies, reducing 
technical variation and accelerating the discovery of robust blood-based miRNAs. Considering the enormous 
scientific interest in miRNA biomarkers, research programs should be better designed, robust, powerful, and 
demonstrate clinical effectiveness. 
miRNA detection methods
MicroRNA quantification is one of the major challenges in the clinic. Historically, the expression of blood-based 
miRNAs must be normalized to single or multiple (preferred) calibrator miRNAs or genes. Yet, in nearly all 
published studies, a different calibrator is selected for use. Inconsistent normalization profoundly influences the 
calculation of miRNA expression values, affecting the interpretation of results. Generally, as it is very difficult 
for clinical studies to find a consistent calibrator across different patient cohorts, researchers should present 
all their data, including raw Cq values and amplification efficiency. Two recent articles assist with study design 
by suggesting guidelines for selecting miRNAs with valid fluorescence values (i.e. above background noise), 
improving the accuracy and reliability of the published dataset3,4. 
Studies have now indicated that a calibrator gene may not be required at all5,6. We believe that alternative 
approaches such as base line fluorescence and normalization to the fluid volume will be the future methodologies 
for normalizing miRNA biomarker expression. Spike-in strategies are also implemented for normalizing miRNA 
expression, and we caution against this approach as it does not provide a true reflection of the biological content. 
Accelerating miRNA biomarkers efforts with machine learning 
Genetic data acquisition and analysis is improving exponentially. There is a wealth of information available 
from numerous databases around the world. FANTOM5 and TCGA are instances of repositories changing 
our approach to miRNA analysis. Most traditional wet labs lack the bioinformatic expertise in capitalizing on 
these new online sources. This remains one of the challenges for most laboratories requiring access to this 
information. Groups with bioinformatic expertise routinely employ machine learning to mine the data. Machine 
learning algorithms look for miRNA differences between thousands of cancer cases and healthy tissue in these 
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repositories. These custom algorithms are part of pipelines navigating and sweeping through these large swaths 
of data. Programmers assign a task to an algorithm, filtering through genetic markers and patterns, allowing 
the coded algorithm to consistently improve its learning ability in discovering novel patterns of expression. An 
example of this potential is the assistive AI tool from Mirocolus to build LoomBio, mirroring an open-sourced 
IBM Watson for health. From a manually selected dataset of 10,000 miRNAs, LoomBio was trained to provide 
an up-to-date miRNA snapshot. 
Summary
There are many challenges facing researchers and companies invested in the search for clinically relevant miRNA 
biomarkers. However, miRNAs will have no meaningful clinical benefit until the research community produces 
consistent findings. As part of this community, we require a set of rigorous standard operating procedures 
with the ability of being adapted by large consortiums. Furthermore, the uptake of emerging technologies will 
facilitate rapid progress. If these challenges can be met, there is a real possibility of using circulating miRNAs 
as effective tools for the clinical management of human diseases.
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